- Poster presentation
- Published:
Clinical evaluation of endotoxin hemoadsorption therapy (PMX-DHP) for hypercytokinemia caused by septic multiple organ failure
Critical Care volume 8, Article number: P148 (2004)
The limitations of endotoxin hemoadsorption therapy (PMX-DHP) and the optimal time to start PMX-DHP were examined in patients with septic multiple organ failure with hypercytokinemia (IL-6 > 1000 pg/ml). This study included 66 patients with infectious systemic inflammatory response syndrome in whom IL-6 > 1000 pg/ml before PMX-DHP therapy. These subjects were separated into two groups, those who survived for more than 28 days after the start of PMX-DHP therapy (S group; 38 patients) and those who did not survive (N-S group; 28 patients). Severity of symptoms and background factors, hemodynamic parameters, PaO2/FiO2, endotoxin, cytokines (TNF-α, IL-6, IL-1ra), and vascular endothelial cell function-related markers (ICAM-1, ELAM-1, PAI-1) were examined before and after PMX-DHP. Statistical analyses were performed by chi-squared test for background factors, with Wilcoxon's signed rank test for comparison within a group, and Mann–Whitney's U test for comparison between groups. This study was approved by the IRB of Tokyo Medical University.
Results
The APACHE-II score was 22.9 ± 6.3 and 30.7 ± 8.9, and the SOFA score was 9.7 ± 3.6 and 12.6 ± 3.4 in the S and N-S groups, respectively, showing significantly higher scores in the N-S group. The number of days that had lapsed from the onset of shock to PMX-DHP initiation was 0.8 ± 0.8 days in the S group while it was longer (1.8 ± 1.2 days) in the N-S group. After PMX-DHP for 2 hours, the endotoxin level decreased from 26.1 ± 20.3 to 20.3 ± 24.5 pg/ml with statistical significance (P < 0.05) in the S group. In the N-S group, it tended to decrease from 23.6 ± 20.3 to 10.9 ± 17.2 pg/ml.
Conclusion
These results suggest that PMX-DHP could save more lives in patients with septic multiple organ failure with IL-6> 1000 pg/ml when applied early after the onset of shock.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ikeda, T., Ikeda, K., Nagura, M. et al. Clinical evaluation of endotoxin hemoadsorption therapy (PMX-DHP) for hypercytokinemia caused by septic multiple organ failure. Crit Care 8 (Suppl 1), P148 (2004). https://doi.org/10.1186/cc2615
Published:
DOI: https://doi.org/10.1186/cc2615
Keywords
- Emergency Medicine
- Clinical Evaluation
- Rank Test
- Signed Rank Test
- Optimal Time